Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**)

The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk  CNBC With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss

The Wegovy pill is aimed at reducing weight long term, Novo Nordisk notes.

The pill is the first FDA-approved oral GLP-1 medication for weight management.

Annika Kim Constantino / CNBC: FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk … The U.S. Food and Drug Administration on

As we approach the final weeks of 2025, the U.S. healthcare sector has transitioned from a defensive stalwart to a primary market leader. Evidently, while

A growing body of research suggests that older adults are discontinuing GLP-1 medications at high rates, The New York Times reported Dec. 21. Six things

AI Platform to Combat Muscle Loss and Preserve Metabolic Vitality for GLP-1 Users  Morningstar

Applied Nutrition has entered an exclusive three-year agreement with Morrisons to introduce a “GLP-1 friendly” ready-meals range. The post Applied Nutrition partners with Morrisons in

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its

The rise of GLP-1 usage along with other trends converging with obesity and obesity drugs, is prompting interest in weight management formulations within the beverage

Here’s the skinny on Chipotle’s new menu.

2025 is just about in the books, and the reviews are in: It sucked. Over at the subreddit r/decadeology, you can check out a long,

As wellness advice floods social media, experts point to a short list of science-backed habits that improve health—and a few popular resolutions you’re better off

Livelively USA combines AI insights with Eastern wellness principles to support healthier long-term weight management behaviors. NEW YORK, Dec. 22, 2025 /PRNewswire/ — Weight-loss medications

Panuwat Dangsungnoen/Getty Images After a strong year for healthcare funding, VCs plan to back different kinds of AI startups in 2026. Investors expect AI startups

2025 was meant to be the year agrifoodtech found its footing again. Instead, it turned into something messier: a year of recalibration, retrenchment, and some

By Charlotte Huff, KFF Health News David Garza sometimes feels as if he doesn’t have health insurance now that he pays so much to treat

Some experts believe that anyone could benefit from GLP-1 medications, as the popular drugs have become more widespread and accessible. Others, however, warn that the

Las Vegas is getting fancier with amenities like F1 races. Getty Images. Las Vegas is capitalism in its most naked, sometimes exploitative form. I really

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of incretin mimetics, drugs that stimulate insulin release, encompassing semaglutide, tirzepatide and liraglutide that lead to reduced

Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly the problem Eli Lilly (LLY) seems to

The popularity of Ozempic and other GLP-1 weight-loss drugs is prompting many affluent women to clear out their closets—a boon to savvy thrifters. For 10

Pharmaceuticals, Vol. 19, Pages 9: Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease

As GLP-1s grow in popularity, more Americans are rethinking weight loss in the new year KIRKLAND, Wash, Dec. 19, 2025 /PRNewswire/ — A new survey

The Trump administration finalized agreements Dec. 19 with nine pharmaceutical manufacturers to offer U.S. patients prescription drug prices aligned with the lowest rates paid by

People with type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists were more likely to develop chronic cough than people using other second-line medications, a

GLP-1 medications are prescription treatments used in the UK to manage type 2 diabetes and, in certain cases, medically supervised weight loss. They function by

The debate over whether insurers should pay for GLP-1 drugs like Ozempic and Wegovy has revived a familiar American argument about why people get sick.

Novo Nordisk NVO announced the submission of a new drug application (NDA) to the FDA, seeking approval for its next-generation once-weekly injection, CagriSema, to reduce excess

Plus, news on: EpimAb, Boehringer and Nxera, Syneron, Amphix Altimmune goes to Phase 3 in MASH: The drug developer’s Phase 2 trial of pemvidutide, a

Quick Read Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss after patients switched from injections. Lilly’s Zepbound

Ozempic and similar weight loss drugs have been found to cut risks for a variety of health issues — ranging from heart to kidney disease

GLP-1 pills are on the way. Here’s what to know : Short Wave  NPR Wegovy Maker Novo Nordisk Files for FDA Approval of Obesity Drug CagriSema  The

IJMS, Vol. 27, Pages 27: The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review International Journal of Molecular

Publication date: 20 December 2025–2 January 2026 Source: The Lancet, Volume 406, Issue 10522 Author(s): Edith Wing-Kar Chow, Elaine Chow